T1	Participants 56 128	metastatic and/or unresectable malignant gastrointestinal stromal tumors
T2	Participants 351 454	patients with CD117(+) unresectable and/or metastatic malignant gastrointestinal stromal tumors (GISTs)
T3	Participants 657 918	Two open-label, controlled, multicenter, intergroup, international, randomized phase III studies were submitted -- one conducted by the European Organization for Research and Treatment of Cancer (n = 946) and the other by the Southwest Oncology Group (n = 746).
